[摘要] 目的 探討注射用生長抑素治療肝硬化食管胃底靜脈曲張破裂出血的效果。方法 采用隨機(jī)數(shù)字法將方便選取的2016年1月—2017年2月該院消化科室78例肝硬化食管胃底靜脈曲張破裂出血患者分為參照組和研究組進(jìn)行統(tǒng)計分析，每組實驗樣本確定為39例，參照組采用埃索美拉唑治療，研究組采用生長抑素治療，評估兩組患者的治療效果、治療前及治療后24、72 h嘔血次數(shù)、嘔血量、黑便次數(shù)、黑便量、平均止血時間、平均輸血量以及不良反應(yīng)發(fā)生率。結(jié)果 研究組患者的治療總有效率（94.87%）高于參照組（76.92%）；治療后24、72 h研究組患者的嘔血次數(shù)、嘔血量、黑便次數(shù)以及黑便量少于參照組；平均止血時間短于參照組，平均輸血量少于參照組；不良反應(yīng)發(fā)生率（2.50%）低于參照組（17.90%）（P<0.05）。結(jié)論 采用生長抑素治療肝硬化食管胃底靜脈曲張破裂出血患者，患者的治療效果顯著，治療后24、72 h嘔血次數(shù)、嘔血量、黑便次數(shù)以及黑便量較少，平均止血時間較短，平均輸血量少，不良反應(yīng)發(fā)生率低，要用安全性較高，值得臨床學(xué)習(xí)。
　　[關(guān)鍵詞] 生長抑素；肝硬化食管胃底靜脈曲張破裂出血；臨床效果
　　[中圖分類號] R4 [文獻(xiàn)標(biāo)識碼] A [文章編號] 1674-0742（2018）01（c）-0135-04
　　[Abstract] Objective This paper tries to investigate the effect of somatostatin injection in the treatment of esophageal variceal rupture of cirrhosis. Methods A total of 78 patients with cirrhotic esophageal and gastric variceal rupture from January 2016 to February 2017 in digestive department were convenient selected and by random number method， they were divided into two groups： the control group and the study group. The experimental samples were identified as 39 cases in each group， The control group was treated with esomeprazole and the study group was treated with somatostati， the therapeutic effect of the two groups was evaluated. The number of hematemesis， the number of vomiting blood， the number of melena， the amount of black chop， the time of hemostasis， mean blood transfusion and the incidence of adverse reactions after 24 and 72 hours of treatment. Results The total effective rate（94.87%） was higher in the study group than in the control group （76.92%）. The number of hematemesis， hematemesis， melatonin and black volume were lower in the study group at 24 and 72 hours after treatment. The average hemostasis time was shorter than the control group， the average blood transfusion less than the control group. The incidence of adverse reactions was 2.50% lower than that of the reference group of 17.90%（P<0.05）. Conclusion The effect of somatostatin on the treatment of cirrhosis， esophageal and gastric variceal bleeding is significant. The number of hematemesis， hematemesis， the number of melena and the amount of melena are lower at 24 and 72 hours after treatment， and the average hemostasis is shorter， the average blood transfusion is less， the incidence of adverse reactions is fewer， with higher safety of medicine， which is worthy of clinical study.
　　[Key words] Somatostatin； Cirrhosis esophageal variceal bleeding； Clinical effect
　　食管靜脈曲張破裂出血是肝硬化較為常見的并發(fā)癥，該病的發(fā)病率較高，有關(guān)研究表明，該病的發(fā)病率大約在5%～15%之間，再次出血率及病死率分別達(dá)到50%和30%以上，嚴(yán)重影響患者的生命健康和生活質(zhì)量。因此，臨床上需要采用積極有效的治療方法控制并預(yù)防患者出現(xiàn)再出血[1]。目前，臨床上采用的藥物治療在食管靜脈曲張破裂出血方面得到較好的應(yīng)用，一方面可使得患者獲得了良好的止血效果，另一方面不對患者的血流動力學(xué)改變造成較大的影響，無嚴(yán)重的不良反應(yīng)，藥用安全性高。該次研究就2016年1月—2017年2月該院消化科室收治的78例肝硬化食管胃底靜脈曲張破裂出血患者進(jìn)行分析，報道如下。

相關(guān)熱詞搜索：食管 肝硬化 靜脈曲張 破裂 出血